Stephan Grupp MD PhD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Stephan Grupp MD PhD sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials 8 currently recruiting early-phase tilt upper quartile by trial count

Stephan Grupp MD PhD: 8 sponsored US clinical trials, 8 recruiting.

Stephan Grupp MD PhD sponsors 8 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is B Lineage Lymphoblastic Lymphoma, with 2 trials.

Upper-quartile sponsor footprint

Stephan Grupp MD PhD sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

8 total, page 1 of 1

RECRUITING Phase 1

CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia

NCT07464951
RECRUITING Phase 2

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

NCT05029336
RECRUITING Phase 1

PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

NCT07007117
RECRUITING Phase 1

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

NCT06934382
RECRUITING Phase 1

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma

NCT05650749
RECRUITING Phase 1

Co-administration of CART22-65s and huCART19 for B-ALL

NCT05674175
RECRUITING Phase 1

Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

NCT05480449
RECRUITING Phase 2

Orphan Indications for CD19 Redirected Autologous T Cells

NCT04276870

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2

Therapeutic Areas

B Lineage Lymphoblastic Lymphoma 2
Relapsed Neuroblastoma 2
Refractory Neuroblastoma 2
High-risk Neuroblastoma 2
T-Cell Acute Lymphoblastic Leukemia/Lymphoma 1
Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation 1
Infants With Very High Risk KMT2A B-ALL 1
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL 1
Metastatic Retinoblastoma 1
B-cell Acute Lymphoblastic Leukemia (B-ALL) 1

What is open in the Stephan Grupp MD PhD pipeline

8 recruiting of 8 indexed (100% open).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: B Lineage Lymphoblastic Lymphoma (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Stephan Grupp MD PhD: open-pipeline peers nationwide

Peers matched on 8 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Stephan Grupp MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0246810 0%50%100%150% Total trials Recruiting share Stephan Grupp MD PhDAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)AAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Stephan Grupp MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Stephan Grupp MD PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Stephan Grupp MD PhD page

8 registered trials is a research-attention snapshot, not an endorsement of Stephan Grupp MD PhD or any single study.

  • 8 of Stephan Grupp MD PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • B Lineage Lymphoblastic Lymphoma is the condition Stephan Grupp MD PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See B Lineage Lymphoblastic Lymphoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Stephan Grupp MD PhD pipeline card: 8 registered trials from official public datasets.Report a data error.